EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study

Jie Wang iD, Shanshan Qi iD, Siyuan Chen iD, Hang Yu iD

Cardiovascular Therapeutics · 2026

DOI: 10.1155/cdr/5113761 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Jie Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Atrial Fibrillation, Diabetes Mellitus, Type 2, Cardiomyopathy, Dilated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Projects of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dilated cardiomyopathy (DCM) is characterized by left ventricular dilation and systolic dysfunction in the absence of severe hypertension, valvular disease, or coronary artery disease. Patients with DCM have a high risk of atrial fibrillation (AF), especially when combined with Type 2 diabetes mellitus (T2DM). Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have shown cardioprotective effects in patients with diabetes, suggesting potential benefits in reducing AF incidence.

Methods

We retrospectively analyzed clinical data from patients with T2DM diagnosed with DCM treated at the First Affiliated Hospital of Xi’an Jiaotong University between January 2018 and January 2024. Patients were divided into two groups based on their use of SGLT2i. The incidence of AF was compared between these groups using logistic regression models adjusted for potential confounders, including demographic characteristics, comorbidities, and medication history. Additionally, a subgroup analysis was conducted to evaluate the relationship between AF and SGLT2i.

Results

Among 455 enrolled patients, 95 (20.9%) were treated with SGLT2i. The incidence of AF was significantly lower in the SGLT2i group compared with the control group (7/95 [7.4%] vs. 68/360 [18.9%]; OR = 0.308, 95 % CI = 0.132–0.735, p = 0.008). Subgroup analyses showed consistent results across various age, gender, hypertension status, and diabetes duration groups, indicating the robustness of the association between SGLT2i use and reduced AF incidence.

Conclusion

Our study suggests that SGLT2i use is associated with a lower incidence of AF in patients with T2DM and DCM. This observed association warrants further investigation in prospective studies to elucidate its nature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAtrial FibrillationDiabetes Mellitus, Type 2Cardiomyopathy, DilatedRetrospective StudiesIncidenceChinaCase-Control StudiesFollow-Up StudiesHumansMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

Type 2 diabetes mellitusatrial fibrillationcohort studydilated cardiomyopathysodium-glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn.
  • Department of Health Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn.
  • Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn.

ORCID-Profile: Jie Wang, Shanshan Qi, Siyuan Chen, Hang Yu

Förderung

  • Key Research and Development Projects of Shaanxi Province

Zitieren

APA

Wang, J., Qi, S., Chen, S., & Yu, H. (2026). Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/5113761

Vancouver

Wang J, Qi S, Chen S, Yu H. Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/5113761

BibTeX
@article{Wang2026,
  author = {Wang, Jie and Qi, Shanshan and Chen, Siyuan and Yu, Hang},
  title = {Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  doi = {10.1155/cdr/5113761}
}
Kostenlos starten →